Neue Medikamente, neue Nebenwirkungen? – Nebenwirkungen von Immuntherapien

Das letzte Jahrzehnt hat diverse Therapieansätze hervorgebracht, die die Behandlung onkologischer Patienten verändert haben. Die klassische Chemotherapie wurde bei vielen Entitäten durch immunmodulierende Ansätze erweitert und teilweise ersetzt. Dieser Eingriff in das Immunsystem und der Einsatz zielgerichteter Therapien bringen ein neues Spektrum von Nebenwirkungen mit sich, das komplexer zu behandeln ist als die zytotoxischen Nebenwirkungen von Chemotherapien.

Schlüsselwörter

Nebenwirkungen - Immuntherapien - Toxizitäten

Publication History

Article published online:
08 December 2025

• Literatur

• 1 Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol 2024; 143: 113365
• 2 Wei J, Yang Y, Wang G. et al. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol 2022; 13: 1035276
• 3 Guedan S, Calderon H, Posey Jr AD. et al. Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev 2019; 12: 145-156
• 4 Khongorzul P, Ling CJ, Khan FU. et al. Antibody-Drug Conjugates: A Comprehensive Review. Mol Cancer Res 2020; 18 (01) 3-19
• 5 Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: Building a bridge over troubled waters. Cell 2022; 185 (15) 2770-2788
• 6 Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer 2023; 9 (07) 543-553
• 7 Haanen J, Obeid M, Spain L. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33 (12) 1217-1238
• 8 Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol 2018; 19 (Suppl. 1) 31-39
• 9 Sedano R, Cabrera D, Jimenez A. et al. Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. Am J Gastroenterol 2022; 117 (12) 1917-1932
• 10 Cukier P, Santini FC, Scaranti M. et al. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 2017; 24 (12) T331-T347
• 11 Palaskas NL, Ali HJ, Koutroumpakis E. et al. Cardiovascular toxicity of immune therapies for cancer. BMJ 2024; 385: e075859
• 12 Altan M, Zhong L, Shannon VR. et al. Pulmonary Toxicities of Immunotherapy. Adv Exp Med Biol 2021; 1342: 357-375
• 13 Hines MR, Knight TE, McNerney KO. et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther 2023; 29 (07) 438 e1-e16
• 14 Chohan KL, Siegler EL, Kenderian SS. CAR-T Cell Therapy: the Efficacy and Toxicity Balance. Curr Hematol Malig Rep 2023; 18 (02) 9-18
• 15 Gust J. BCMA-CAR T-cell treatment-associated parkinsonism. Blood 2023; 142 (14) 1181-1183
• 16 Markides DM, Hita AG, Merlin J. et al. Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know. Ann Emerg Med 2025; 85 (03) 214-229
• 17 Chennamadhavuni A, Abushahin L, Jin N. et al. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Front Immunol 2022; 13: 779691